BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced inducement stock-option grants awarded Feb 10, 2026, to two employees hired in January 2026 under its 2025 Inducement Plan.

The awards total 65,350 non-qualified stock options at an exercise price of $10.84 per share, vesting 25% after one year then monthly over 36 months. Grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

Key Figures

Current share price: $10.84 Inducement option shares: 65,350 shares Par value: $0.0001 per share +3 more

6 metrics

Current share price $10.84 Closing price used as exercise price for inducement options

Inducement option shares 65,350 shares Aggregate non-qualified stock options granted to new employees

Par value $0.0001 per share Par value of BBOT common stock underlying inducement options

Initial vesting tranche 1/4 of award Vests on first anniversary of employee start date

Monthly vesting period 36 months Equal monthly installments after first anniversary, subject to service

New hires covered 2 employees Inducement awards for individuals hired in January 2026

Market Reality Check

Price: $12.04 Vol: Volume 331,266 is 21% abo...

normal vol

$12.04 Last Close

Volume Volume 331,266 is 21% above the 20-day average of 274,263, indicating slightly elevated trading ahead of this HR-related update. normal

Technical Shares at $10.84 are trading below the 200-day MA of $11.58, reflecting a weaker medium-term trend.

Peers on Argus

BBOT was up 1.5% pre-news, while peers were mixed: AVXL -8.76%, PRAX -1.51%, ver...

BBOT was up 1.5% pre-news, while peers were mixed: AVXL -8.76%, PRAX -1.51%, versus IMNM +1.01% and IVA +2.95%. This pattern points to stock-specific trading rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Jan 13 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Inducement grant	Neutral	+4.6%	Stock option inducement grant for a new hire under 2025 Inducement Plan.
Jan 07	Clinical data update	Positive	+4.4%	Preliminary Phase 1 safety and antitumor data across three RAS/PI3Kα programs.
Dec 16	Conference presentation	Neutral	-1.3%	Announcement of leadership presentation at the J.P. Morgan Healthcare Conference.
Dec 11	Inducement grant	Neutral	-1.9%	Inducement stock option grant for a November 2025 hire under Nasdaq Rule 5635(c)(4).
Dec 10	Preclinical data	Positive	+2.8%	Late-breaking preclinical data on BBO-10203 as a first-in-class RAS:PI3Kα breaker.

Pattern Detected

BBOT has shown positive reactions to clinical data updates, while routine corporate or inducement announcements have produced smaller, mixed price moves.

Recent Company History

Over the last few months, BBOT highlighted several milestones, including preliminary Phase 1 data across three RAS/PI3Kα programs on Jan 7, 2026, which saw a +4.36% move. Multiple prior inducement grants under the 2025 Inducement Plan in December 2025 and January 2026 produced modest, mixed reactions (from -1.95% to +4.6%). Preclinical data on BBO-10203 in December 2025 also coincided with a +2.79% move, underscoring that clinical and preclinical updates have been the more impactful catalysts than hiring-related option grants.

Market Pulse Summary

This announcement details inducement stock option grants for two recent hires, covering 65,350 share...

Analysis

This announcement details inducement stock option grants for two recent hires, covering 65,350 shares at an exercise price of $10.84 under the 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Historically, BBOT’s more meaningful price moves followed clinical and preclinical data updates, while prior inducement grants produced modest, mixed reactions. Investors may focus on how such equity awards fit into overall compensation and dilution alongside upcoming clinical milestones and regulatory disclosures.

Key Terms

non-qualified stock options, inducement grants, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

inducement grants financial

"today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026.

The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

What did BBOT announce about inducement grants on February 11, 2026?

BBOT announced the award of inducement option grants totaling 65,350 shares to two new hires. According to BridgeBio Oncology Therapeutics, the grants were made Feb 10, 2026 under the company’s 2025 Inducement Plan and approved by the compensation committee.

How many options and what exercise price were included in BBOT's inducement awards (BBOT)?

The inducement awards total 65,350 non-qualified stock options with an exercise price of $10.84 per share. According to BridgeBio Oncology Therapeutics, $10.84 equals the Nasdaq closing price on the effective grant date.

What is the vesting schedule for the BBOT inducement stock options?

The options vest 25% after one year, then in 36 equal monthly installments thereafter. According to BridgeBio Oncology Therapeutics, vesting is subject to each employee’s continued service through applicable vesting dates.

Under which plan were BBOT’s inducement awards granted and why?

The awards were granted under BBOT’s 2025 Inducement Plan as material inducements for new employment. According to BridgeBio Oncology Therapeutics, the plan was adopted by the board in October 2025 and used per Nasdaq Listing Rule 5635(c)(4).

Were BBOT’s inducement awards approved by independent directors or a committee?

Yes, the compensation committee approved the awards; the committee comprises solely independent directors. According to BridgeBio Oncology Therapeutics, the committee approved the grants as a material inducement to hire the two employees.

Do BBOT’s inducement grants come from shareholder-approved equity incentive plans?

No, the awards were granted outside the company’s stockholder-approved equity incentive plans. According to BridgeBio Oncology Therapeutics, the grants were made pursuant to the separate 2025 Inducement Plan adopted by the board.